Since 1901, we’ve been dedicated to bringing effective medicines to the world.

Established in Jerusalem in 1901, the company known today as Teva started out as a small business distributing imported medicines throughout the land, using mule trains and camel caravans. The young company was named after its pharmacist founders: Salomon, Levin and Elstein Ltd.
Over the following decades, demand for locally produced medicines grew, spurring the company’s growth. In 1976, the company became Teva (the Hebrew word for “nature”) Pharmaceutical Industries Ltd.
Today, Teva in the US is a proud part of Israeli-based Teva Pharmaceuticals Industries Ltd. We are among the top 10 pharmaceutical companies*, a world leader in generic and specialty medicines.
Teva has grown significantly across the globe through numerous successful acquisitions. The timeline of acquisitions below highlights the expansion of Teva’s presence in the United States, which have integrated and enhanced our expertise in new therapeutic areas and markets.
1985: A joint company, established by Teva and W.R. Grace in the US, acquires Lemmon Pharmacal Company. Teva later buys out W.R. Grace’s share, creating Teva Pharmaceuticals USA.
1996: Biocraft in the US joins Teva’s Active Pharmaceutical Ingredient (API) Division.
1999: Teva strengthens its position in the US generic pharmaceuticals market by acquiring Copley Pharmaceutical Inc.
2000: Teva acquires Novopharm Ltd., Canada's second largest generic drug company.
2001: Teva gains full ownership of Teva-Marion Partners, renamed Teva Neuroscience, marketing innovative products in North America.
2004: Teva acquires Sicor, Inc. This acquisition brings together two premier generic pharmaceutical companies, combining Teva's successful oral dose generic drugs franchise with Sicor's leading generic injectable business.
2006: Teva acquires IVAX Corporation, strengthening its R&D, respiratory, manufacturing and marketing presence.
2008: Teva acquires Barr Pharmaceuticals, Inc., expanding Teva’s generic and proprietary portfolios to include women’s health and other important therapeutic areas.
2008: Teva acquires CoGenesys, broadening Teva’s biopharmaceuticals capabilities.
2011: Teva acquires Cephalon, Inc. to diversify and expand its portfolio of branded and specialty pharmaceuticals, including the areas of CNS and oncology.
2013: Teva acquires MicroDose Therapeutx, expanding Teva’s respiratory and drug delivery portfolios.
2014: Teva acquires NuPathe and Labrys Biologics, greatly complementing its expanding pain care portfolio within CNS.
View the full history of Teva worldwide on our global corporate website.
*[IMS Health, MIDAS Sales Sep 2013]